Seroatlas · Human Serome Atlas

TFPI2

Tissue factor pathway inhibitor 2

Also known as: PP5, REF1, TFPI-2, TFPI2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P48307
Gene: TFPI2
Ensembl: ENSG00000105825
Chromosome: 7
Canonical length: 235 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Secretome location: Secreted to extracellular matrix

OverviewNCBI Gene

This gene encodes a member of the Kunitz-type serine proteinase inhibitor family. The protein can inhibit a variety of serine proteases including factor VIIa/tissue factor, factor Xa, plasmin, trypsin, chymotryspin and plasma kallikrein. This gene has been identified as a tumor suppressor gene in several types of cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]

Canonical amino-acid sequenceUniProt

235 residues, UniProt reviewed canonical sequence.

>P48307|TFPI2
     1  MDPARPLGLS ILLLFLTEAA LGDAAQEPTG NNAEICLLPL DYGPCRALLL RYYYDRYTQS
    61  CRQFLYGGCE GNANNFYTWE ACDDACWRIE KVPKVCRLQV SVDDQCEGST EKYFFNLSSM
   121  TCEKFFSGGC HRNRIENRFP DEATCMGFCA PKKIPSFCYS PKDEGLCSAN VTRYYFNPRY
   181  RTCDAFTYTG CGGNDNNFVS REDCKRACAK ALKKKKKMPK LRFASRIRKI RKKQF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TFPI2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 900 nTPM

Expression across tissuesHPA

Tissue

placenta: 900 nTPM
pancreas: 72 nTPM
adipose tissue: 66 nTPM
retina: 48 nTPM
ovary: 44 nTPM
adrenal gland: 38 nTPM

Single-cell type

syncytiotrophoblasts: 2,541 nCPM
epididymal basal cells: 2,412 nCPM
pancreatic duct cells: 1,123 nCPM
endometrial luminal cells: 756 nCPM
endometrial glandular cells: 438 nCPM
fallopian secretory cells: 406 nCPM

Immune cell

total PBMC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

medulla oblongata: 10 nTPM
hypothalamus: 7.8 nTPM
cerebral cortex: 2.6 nTPM
thalamus: 2.2 nTPM
choroid plexus: 1.5 nTPM
white matter: 0.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.22
gnomAD pLI: 0
gnomAD missense Z: -0.15
DepMap mean gene effect: 0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

blood coagulation

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TFPI2 as an antibody target. Whether an autoantibody or antibody against TFPI2 could matter depends on whether native TFPI2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TFPI2 is annotated as secreted, so native TFPI2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label TFPI2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...